Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Classic Prognostic Factors Tumor Stage, Tumor Size, and Tumor Grade are the Strongest Predictors of Outcome in Synovial Sarcoma: No Role for SSX Fusion Type or Ezrin Expression

The Classic Prognostic Factors Tumor Stage, Tumor Size, and Tumor Grade are the Strongest... Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE The Classic Prognostic Factors Tumor Stage, Tumor Size, and Tumor Grade are the Strongest Predictors of Outcome in Synovial Sarcoma No Role for SSX Fusion Type or Ezrin Expression Suzan E. ten Heuvel, MD,* Harald J. Hoekstra, MD, PhD,* Esther Bastiaannet, MSc,* and Albert J. H. Suurmeijer, MD, PhDw Conclusions: Disease stage at presentation, tumor size, and Background: The aim of this study was to investigate prognostic tumor grade were significant predictors of survival in synovial factors influencing the survival of synovial sarcoma, including sarcoma. SYT-SSX fusion type was not correlated with survival the debated role of SYT-SSX fusion type and the newly in our series. Ezrin expression levels were not discriminative in suggested immunohistochemical marker ezrin. predicting outcome. Patients and Methods: From 1984 to 2005, 45 patients—25 men Key Words: sarcoma, treatment, pathology, metastases, prog- (56%) and 20 women (44%) with a median age of 31 (range: nosis 2 to 81) years—were diagnosed with a synovial sarcoma. Age (Appl Immunohistochem Mol Morphol 2009;17:189–195) at diagnosis, tumor site, tumor size, tumor histology (biphasic vs. monophasic), mitotic count, necrosis, histologic grade, SYT- SSX fusion type, and ezrin immunostaining were analyzed for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

The Classic Prognostic Factors Tumor Stage, Tumor Size, and Tumor Grade are the Strongest Predictors of Outcome in Synovial Sarcoma: No Role for SSX Fusion Type or Ezrin Expression

Loading next page...
 
/lp/wolters-kluwer-health/the-classic-prognostic-factors-tumor-stage-tumor-size-and-tumor-grade-P0qjLJxKDG
Publisher
Wolters Kluwer Health
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31818a6f5c
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE The Classic Prognostic Factors Tumor Stage, Tumor Size, and Tumor Grade are the Strongest Predictors of Outcome in Synovial Sarcoma No Role for SSX Fusion Type or Ezrin Expression Suzan E. ten Heuvel, MD,* Harald J. Hoekstra, MD, PhD,* Esther Bastiaannet, MSc,* and Albert J. H. Suurmeijer, MD, PhDw Conclusions: Disease stage at presentation, tumor size, and Background: The aim of this study was to investigate prognostic tumor grade were significant predictors of survival in synovial factors influencing the survival of synovial sarcoma, including sarcoma. SYT-SSX fusion type was not correlated with survival the debated role of SYT-SSX fusion type and the newly in our series. Ezrin expression levels were not discriminative in suggested immunohistochemical marker ezrin. predicting outcome. Patients and Methods: From 1984 to 2005, 45 patients—25 men Key Words: sarcoma, treatment, pathology, metastases, prog- (56%) and 20 women (44%) with a median age of 31 (range: nosis 2 to 81) years—were diagnosed with a synovial sarcoma. Age (Appl Immunohistochem Mol Morphol 2009;17:189–195) at diagnosis, tumor site, tumor size, tumor histology (biphasic vs. monophasic), mitotic count, necrosis, histologic grade, SYT- SSX fusion type, and ezrin immunostaining were analyzed for

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: May 1, 2009

There are no references for this article.